



May 3, 2021

## Zenas BioPharma Announces New Executive Leadership Appointments

*Hua Mu, MD, Ph.D. appointed President, CEO and Acting CMO*

*Joe Farmer appointed CBO*

HONG KONG and BOSTON, May 3, 2021 (GLOBE NEWSWIRE) — Zenas BioPharma (“Zenas”), a cross-border (China-USA based) biopharmaceutical company committed to the development and delivery of immune-based therapies, today announced the appointment of Hua Mu, MD, Ph.D. as President and Chief Executive Officer and Acting Chief Medical Officer and Joe Farmer as Chief Business and Administrative Officer.

“We are delighted to have Hua join the Zenas executive leadership team,” said Lonnie Moulder, Founder and Executive Chairman. “His extensive experience, including building and leading R&D organizations in China, and his track record of successful development and approval of new drugs in the US and China will be critical as Zenas builds a global organization and advances its innovative pipeline of immune-based therapies.”

Dr. Mu joins Zenas after co-founding Overland Pharmaceuticals and serving as Interim Chief Executive Officer and Chief Medical Officer, while also serving as Venture Partner at Hillhouse Capital. Prior to Overland, Dr. Mu served as Chief Scientific Officer and President of R&D and later Chief Medical Officer of Simcere Pharmaceutical Group and President of Simcere of America Inc. Before Simcere, he was Senior Vice President and Global Head of Product Development Service and Partnership at WuXi AppTec. Prior to WuXi, he was Executive Vice President and Chief Medical Officer at Hutchison MediPharma in China. He previously held clinical development executive roles at several global pharmaceutical companies in the US, including Biogen and Genentech.

Dr. Mu received his Ph.D. from the University of California at Berkeley and completed his post-doctorate training at University of California at San Francisco School of Medicine and University of Washington School of Medicine. He received his MD degree from West China University of Medical Sciences.

“Zenas is an innovative biopharmaceutical company uniquely positioned at the nexus of drug development and product flow between China and the West, with an exceptional management team, a world class investor base, and an impressive pipeline of differentiated programs,” said Dr. Mu. “I am thrilled to work with the entire Zenas team and network of partners to achieve our mission to transform the lives of patients with unmet medical needs by bringing best-in-class immune-based therapies to the world.”

Zenas also announced the appointment of Joe Farmer as Chief Business and Administrative Officer. Mr. Farmer is an accomplished biopharma executive with approximately 25 years of transactional and operational experience working with emerging biotechnology companies at all stages of development, from discovery through commercialization. Prior to joining Zenas, Mr. Farmer served as Chief Operating Officer at Xilio Therapeutics.

Prior to Xilio, Mr. Farmer was the General Counsel and Corporate Secretary at TESARO, where he led the global legal, compliance and government affairs functions and was a key member of the leadership team through its acquisition by GlaxoSmithKline in 2019. He previously served as Chief Corporate Counsel at Cubist Pharmaceuticals through its acquisition by Merck in 2015 and served at other publicly traded companies as General Counsel and Chief Administrative Officer. Mr. Farmer began his career as a corporate attorney at Testa Hurwitz & Thibault. He received his J.D. from Boston College Law School.

“With the appointments of Hua and Joe, Zenas has further strengthened its executive leadership team,” said Lonnie Moulder. “Their respective expertise in building global organizations and executing corporate development strategy through all phases of drug development and commercialization will be invaluable as we continue to advance our global development programs and expand our novel pipeline.”

## **About Zenas BioPharma**

Zenas BioPharma is a cross-border (China-USA based) biopharmaceutical company committed to becoming a global leader in the development and delivery of immune-based therapies for patients in China and around the world. Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit [www.zenasbio.com](http://www.zenasbio.com) and follow us on Twitter at [@ZenasBioPharma](https://twitter.com/ZenasBioPharma) and [LinkedIn](https://www.linkedin.com/company/zenasbio).

## **Contacts**

Investor Contact:  
Zenas BioPharma  
[IR@zenasbio.com](mailto:IR@zenasbio.com)

Media Contact:  
Lauren Bartlett  
Zenas BioPharma  
[lauren.bartlett@zenasbio.com](mailto:lauren.bartlett@zenasbio.com)

# Zenas BioPharma 宣布任命新任高管

*牟骅博士被任命为总裁、首席执行官兼代理首席医疗官*

*Joe Farmer 被任命为首席商务官*

香港和波士顿, May 03, 2021 (GLOBE NEWSWIRE) -- 致力于开发和提供免疫疗法的跨国（中国-美国）生物制药公司 Zenas BioPharma（以下称“Zenas”）今天宣布，任命牟骅博士为总裁兼首席执行官及代理首席医疗官，任命 Joe Farmer 为首席商务和行政官。

“我们很高兴牟骅能够加入 Zenas 的高管团队，”公司创始人兼执行主席 Lonnie Moulder 表示，“他拥有在中国建立和领导研发组织等方面的丰富经验，以及在美国和中国成功开发新药和获得监管审批的往绩，这些对于 Zenas 建立全球组织并推进基于免疫疗法的创新产品管线将发挥至关重要的作用。”

在加入 Zenas 之前，牟博士作为联合创始人建立了瓴路药业，担任临时首席执行官兼首席医疗官，同时还担任高瓴资本的风险合伙人。在任职瓴路药业之前，牟博士曾担任先声药业集团首席科学官兼研发总裁，后又担任首席医疗官，以及和 Simcere of America Inc. 公司总裁。在供职先声药业之前，他在药明康德公司担任高级副总裁兼产品开发服务和合作伙伴关系全球负责人。在药明康德工作之前，他在中国担任和黄医药执行副总裁兼首席医疗官。此前，他曾在包括 Biogen 和基因泰克在内的多家全球制药公司担任临床开发高管职务。

牟博士在加州大学伯克利分校获得博士学位，并在加州大学旧金山医学院和华盛顿大学医学院完成博士后课程。他拥有华西医科大学医学博士学位。

“Zenas 是一家独特定位于中国和西方之间药物开发和产品流动连结点的创新型生物制药公司，拥有出色的管理团队、世界一流的投资者群体以及令人瞩目的差异化项目组合，”牟博士表示，“我非常高兴能与整个 Zenas 团队和合作伙伴网络合作，通过向世界提供一流的免疫疗法来实现我们的使命，为医疗需求尚未得到满足的广大患者的生活带来改变。”

Zenas 还宣布任命 Joe Farmer 为首席商务和行政官。Farmer 先生是一位成功的生物制药高管，拥有多家新兴生物科技公司中交易和运营领域约 25 年的工作经验，涉及从药物发现到商业化的开发过程各个阶段。加入 Zenas 之前，Farmer 先生在 Xilio Therapeutics 担任首席运营官。

在任职 Xilio 之前，Farmer 先生在 TESARO 担任总法律顾问和公司秘书，领导全球法律、合规和政府事务职能部门，并通过 2019 年 GlaxoSmithKline 的收购而成为该公司领导团队的关键成员。此前，通过 Merck 公司在 2015 年的收购，他曾担任 Cubist Pharmaceuticals 公司首席法律顾问，并曾在其他上市公司担任总法律顾问和首席行政官。Farmer 先生从

担任 Testa Hurwitz & Thibault 公司的企业律师开始了职业生涯。他曾获波士顿大学法学院法学博士学位。

“牟骅和 Joe 的任命进一步壮大了 Zenas 的高管团队，” Lonnie Moulder 表示，“他们在建立全球性组织和在药物开发和商业化的各个阶段执行企业发展战略方面各具专长，这将是我们将继续推进全球发展计划和扩大我们创新产品管线工作中的宝贵财富。”

## 关于 Zenas BioPharma

Zenas BioPharma 是一家跨国（美国-中国）生物制药公司，致力于成为中国和世界各地患者免疫疗法开发和交付的全球领先企业。Zenas 的创新治疗药物深度研发管线正在快速推进，并通过我们成功的业务发展战略不断发展。我们经验丰富的领导团队和我们的业务合作伙伴网络将推动卓越运营，以提供潜在的变革性疗法来改善自身免疫性疾病和罕见疾病患者的生活。”要了解有关 Zenas BioPharma 的更多信息，请访问 [www.zenasbio.com](http://www.zenasbio.com)，并通过 Twitter ([@ZenasBioPharma](https://twitter.com/ZenasBioPharma)) 和 [LinkedIn](https://www.linkedin.com/company/zenasbio) 关注我们。

## 联系人

投资者关系联系方式:

Zenas BioPharma  
[IR@zenasbio.com](mailto:IR@zenasbio.com)

媒体联系人:

Lauren Bartlett  
Zenas BioPharma  
[lauren.bartlett@zenasbio.com](mailto:lauren.bartlett@zenasbio.com)